TESARO Inc (NASDAQ:TSRO) announced an exclusive, worldwide license agreement and immuno-oncology antibody collaboration. Under the terms of the agreement, TESARO receives rights to monospecific antibody drug candidates targeting TIM-3, LAG-3 and PD-1 and dual reactive antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3. Therapeutic antibodies selected from these programs will form the basis of a strategic platform that will enable TESARO to develop novel monotherapy and combination-based approaches with immuno-oncology and other anti-cancer agents in a variety of indications. Antibody candidates from these programs are expected to enter clinical trials over the next 18 to 24 months. TESARO Inc (NASDAQ:TSRO) stock opened at $31.50 in last trading session, and closed at $38.86, trading in the range of $31.50 – $40.99. The stock showed a positive weekly performance of 23.17%.
Pennsylvania device maker Unilife Corp (NASDAQ:UNIS) raised $60 million through a debt financing agreement with OrbiMed Advisors, news of which sent UNIS shares soaring today. Unilife plans to use the funds to support commercial efforts tied to “several large contracts” that Unilife holds with its customers. Unilife Corp (NASDAQ:UNIS) shares closed at $4.99 on last trade day, by gaining 15.24%. Stock 52 week range is $1.80 – $5.30. Company’s market capitalization is $512.24 million.
On March 11, 2014, Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) reported financial results for the fourth quarter and full year ended December 31, 2013. For the quarter ended December 31, 2013, Chelsea reported a net loss of $5.3 million or ($0.07) per share versus a net loss of $2.2 million or ($0.03) per share for the same period in 2012. For the twelve months ended December 31, 2013, Chelsea reported a net loss of $16.4 million or ($0.24) per share compared to a net loss of $31.7 million of ($0.47) per share for the same period in 2012. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock advanced 13.98% and finished the last session at $5.95. The EPS of the stock remained -0.24. Company’s market capitalization is $466.68 million.
Depomed Inc (NASDAQ:DEPO) reported financial results for the quarter and twelve months ended December 31, 2013. 2013 Financial Highlights: Achieved full year 2013 total product sales of $58.3 million, an increase of 112% over 2012; and fourth quarter 2013 product sales of $18.8 million, an increase of 50% over fourth quarter 2012. Full year 2013 Gralise® (gabapentin) product sales were $36.2 million, an increase of 109% over 2012; fourth quarter 2013 Gralise product sales were $11.7 million, an increase of 55% over fourth quarter 2012. Depomed Inc (NASDAQ:DEPO) stock opened at $14.40 in last trading session and closed at $14.94. The 52 week range of the stock is $4.99 – $15.39 and the day range was $13.80 – $15.39.
Leave a Reply